RESONANCE HEALTH LIMITED Resonance Health Limited Share Price
Equities
RHT
AU000000RHT2
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.082 AUD | -3.53% |
|
+3.80% | +36.67% |
| Sales 2022 | 3.85M 2.54M 202M | Sales 2023 | 4.47M 2.94M 235M | Capitalization | 19.37M 12.75M 1.02B |
|---|---|---|---|---|---|
| Net income 2022 | -1M -658K -52.49M | Net income 2023 | - 0 0 | EV / Sales 2022 | 5.01 x |
| Net cash position 2022 | 6.51M 4.29M 342M | Net cash position 2023 | 6.09M 4.01M 320M | EV / Sales 2023 | 2.97 x |
| P/E ratio 2022 |
-22.4
x | P/E ratio 2023 |
-24.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.37% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.53% | ||
| 1 week | +3.80% | ||
| Current month | +17.14% | ||
| 1 month | +7.89% | ||
| 3 months | +60.78% | ||
| 6 months | +46.43% | ||
| Current year | +36.67% |
1 week
0.08
0.09
1 month
0.060.09
Current year
0.050.09
1 year
0.040.09
3 years
0.040.20
5 years
0.040.33
10 years
0.010.33
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Harrison
CEO | Chief Executive Officer | - | 30/06/23 |
John Olynyk
CTO | Chief Tech/Sci/R&D Officer | - | 23/11/21 |
Mitchell Wells
BRD | Director/Board Member | 48 | 31/03/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitchell Wells
BRD | Director/Board Member | 48 | 31/03/17 |
Martin Blake
CHM | Chairman | - | 03/10/07 |
Simon Panton
BRD | Director/Board Member | - | 04/10/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.082 | -3.53% | 125 494 |
| 26/04/24 | 0.085 | 0.00% | 14,000 |
| 24/04/24 | 0.085 | +4.94% | 12,683 |
| 23/04/24 | 0.081 | +2.53% | 380,000 |
| 22/04/24 | 0.079 | -2.47% | 328,149 |
Delayed Quote Australian S.E., April 29, 2024 at 05:02 am
More quotes
Resonance Health Limited is an Australia-based MedTech company. The Company specializes in the development and delivery of non-invasive medical imaging software and services. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
Calendar
26/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +36.67% | 24.77M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- RHT Stock
